IP Library Granted Patent US 11,826,412
Granted Patent B2
US 11,826,412 · App. 17/680,897 · Granted Nov 28, 2023

Immunogenic composition comprising a fusion peptide derived from superantigen toxoids

Inventors: Mohammad Javad Aman (Rockville, MD); Thomas Kort (Rockville, MD); Arundhathi Venkatasubramaniam (Rockville, MD); Nils Williston (Rockville, MD); Rajan Prasad Adhikari (Rockville, MD); Frederick W. Holtsberg (Rockville, MD)
Assignee: ABVACC, Inc.
A61K39/085A61P31/04C12N15/70A61K2039/53A61K2039/55505A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,826,412
App. No.
17/680,897
Granted
Nov 28, 2023
Kind
B2
Abstract

The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal superantigen (SAg) proteins, or any fragments, variants, or derivatives thereof fused together as a single polypeptide in any order.

Claims (20)

1. An isolated polynucleotide comprising a nucleic acid that encodes an attenuated Staphylococcus aureus -derived superantigen (SAg) SEA toxoid comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 4, wherein the toxoid comprises the four mutations relative to wild-type SEA corresponding to the L48R, D70R, Y92A, and H225A mutations and wherein the toxoid has decreased superantigenic activity and/or is less virulent than a SEA toxoid comprising SEQ ID NO: 3.

2. The isolated polynucleotide of claim 1 , wherein the attenuated SEA toxoid comprises an amino acid sequence at least 97% identical to SEQ ID NO: 4.

3. The isolated polynucleotide of claim 1 , wherein the attenuated SEA toxoid comprises SEQ ID NO: 4.

4. The isolated polynucleotide of claim 1 , comprising the nucleotide sequence SEQ ID NO: 8.

5. The isolated polynucleotide of claim 1 , further comprising a heterologous nucleic acid.

6. The isolated polynucleotide of claim 1 , wherein the heterologous nucleic acid comprises a promoter operably associated with the nucleic acid encoding the oligopeptide.

7. A vector comprising the isolated polynucleotide of claim 1 .

8. The vector of claim 7 , which is a plasmid.

9. A host cell comprising the vector of claim 8 .

10. The host cell of claim 9 , which is a bacterium, an insect cell, a mammalian cell, or a plant cell.

11. The host cell of claim 9 , wherein the bacterium is Escherichia coli.

12. A method of producing a an attenuated Staphylococcus aureus -derived superantigen (SAg) SEA toxoid, comprising culturing the host cell of claim 9 , and recovering the oligopeptide.

13. An isolated polynucleotide comprising a nucleic acid that encodes a multivalent oligopeptide comprising a fusion of two or more attenuated Staphylococcus aureus -derived superantigen (SAg) toxoids arranged in any order, wherein the SAg toxoids can be the same or different, and wherein at least one of the SAg toxoids is the SEA toxoid of claim 1 .

14. The isolated polynucleotide of claim 13 comprising the nucleotide sequence SEQ ID NO: 8.

15. A vector comprising the isolated polynucleotide of claim 13 .

16. The vector of claim 15 , which is a plasmid.

17. A host cell comprising the vector of claim 15 .

18. The host cell of claim 17 , which is a bacterium, an insect cell, a mammalian cell, or a plant cell.

19. The host cell of claim 18 , wherein the bacterium is Escherichia coli.

20. A method of producing a multivalent oligopeptide, the method comprising culturing the host cell of claim 17 and recovering the oligopeptide.

Assignments (3)
CHANGE OF NAME Recorded Dec 22, 2022
From: INTEGRATED BIOTHERAPEUTIC VACCINES, INC.
To: ABVACC, INC.
Reel/Frame 062206/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2022
From: INTEGRATED BIOTHERAPEUTICS, INC.
To: INTEGRATED BIOTHERAPEUTIC VACCINES, INC.
Reel/Frame 059879/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2022
From: AMAN, MOHAMMAD JAVAD; KORT, THOMAS; VENKATASUBRAMANIAM, ARUNDHATHI; WILLISTON, NILS; ADHIKARI, RAJAN PRASAD; HOLTSBERG, FREDERICK W.
To: INTEGRATED BIOTHERAPEUTICS, INC.
Reel/Frame 059103/0353 →